BioCryst Pharmaceuticals, Inc.
BCRXBioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Drugs in Pipeline
18
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Aug 3, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How BCRX's past catalysts played out
Oseltamivir
Influenza
BCX4161
Hereditary Angioedema
BCX7353 capsules
Hereditary Angioedema, HAE
Peramivir
Influenza
Berotralstat
Hereditary Angioedema
BCX7353
Hereditary Angioedema (HAE)
forodesine HCl
Chronic Lymphocytic Leukemia (CLL)
Peramivir 150 mg
Influenza
forodesine hydrochloride
Lymphoma
BCX-1777
Leukemia, Lymphocytic
forodesine hydrochloride (BCX-1777)
Leukemia, T-Cell
Ulodesine (BCX4208) 5 mg
Gout
BCX9930
Paroxysmal Nocturnal Hemoglobinuria
Allopurinol
Gout
Peramivir 200 mg
Influenza
BCX4208
Gout
Forodesine 200 mg
Cutaneous T-cell Lymphoma (CTCL),
ulodesine
Gout
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oseltamivir | Phase 3 | Influenza | - | - |
BCX4161 | Phase 3 | Hereditary Angioedema | - | - |
BCX7353 capsules | Phase 3 | Hereditary Angioedema, HAE | - | - |
Peramivir | Phase 3 | Influenza | - | - |
Berotralstat | Phase 3 | Hereditary Angioedema | - | - |
BCX7353 | Phase 3 | Hereditary Angioedema (HAE) | - | - |
forodesine HCl | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Peramivir 150 mg | Phase 2 | Influenza | - | - |
forodesine hydrochloride | Phase 2 | Lymphoma | - | - |
BCX-1777 | Phase 2 | Leukemia, Lymphocytic | - | - |
forodesine hydrochloride (BCX-1777) | Phase 2 | Leukemia, T-Cell | - | - |
Ulodesine (BCX4208) 5 mg | Phase 2 | Gout | - | - |
BCX9930 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Allopurinol | Phase 2 | Gout | - | - |
Peramivir 200 mg | Phase 2 | Influenza | - | - |
BCX4208 | Phase 2 | Gout | - | - |
Forodesine 200 mg | Phase 2 | Cutaneous T-cell Lymphoma (CTCL), | - | - |
ulodesine | Phase 2 | Gout | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioCryst Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in BioCryst Pharmaceuticals, Inc.'s (BCRX) pipeline across Phase 3, Phase 2. Its lead program is Oseltamivir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioCryst Pharmaceuticals, Inc.'s next FDA catalyst?→
BioCryst Pharmaceuticals, Inc.'s (BCRX) next tracked catalyst is a Earnings expected August 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCRX biotech catalysts?→
Add BCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioCryst Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.